Why Bio-Path's Stock Is Surging Higher Today

by Tanzeel Akhtar, Benzinga Staff Writer

February 10, 2021 2:01 PM | 1 min read | Make a Comment

Bio-Path BPTH shares are trading higher Wednesday after the company announced it received a third U.S. patent grant related to the manufacture of its platform technology.
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease.
Bio-Path shares traded up 150.19% to $13.01 at the time of publication. The stock has a 52-week high of $24.34 and a 52-week low of $2.92.

Posted In: News Movers Trading Ideas why it's moving

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.